

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT INTENTION OF THE CHAIRMAN TO INCREASE SHAREHOLDING IN THE COMPANY

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Zylox-Tonbridge Medical Technology Co., Ltd (the “**Company**”) on a voluntary basis.

The Board was informed by Dr. Jonathon Zhong Zhao (“**Dr. Zhao**”) (the chairman of the Board and an executive Director) of his intention to acquire the shares of the Company (the “**Shares**”) from the open market (the “**Proposed Shareholding Increase**”) within about one week from the date of this announcement, subject to compliance with the applicable laws and regulations. According to Dr. Zhao, it is expected that the aggregate amount of consideration for the Proposed Shareholding Increase would not exceed HK\$5 million.

In addition, Dr. Zhao indicated that the Shares proposed to be acquired would be held for medium- to long-term investment purposes, and he had no present intention to sell such Shares during the twelve months after the acquisition. The Board considers that the Proposed Shareholding Increase demonstrates Dr. Zhao’s confidence towards the prospect and growth potential of the Company.

As at the date of this announcement, Dr. Zhao and parties acting in concert with him, hold 96,272,488 Shares, representing approximately 28.96% of the total share capital of the Company, and options, pursuant to which, a maximum of 1,292,431 Shares, representing approximately 0.39% of the total share capital of the Company, will be issued.

According to the information available to the Company and so far as the Directors are aware, the Proposed Shareholding Increase would not give rise to an obligation to make a mandatory offer under Rule 26 of the Codes on Takeovers and Mergers and Share Buybacks, and there would be sufficient public float of the Shares in issue upon completion of the Proposed Shareholding Increase.

Shareholders and the potential investors of the Company should note that as at the date of this announcement, Dr. Zhao has not proceeded with the Proposed Shareholding Increase. The Proposed Shareholding Increase will be subject to the market conditions and will be at the absolute discretion of Dr. Zhao. Shareholders and the potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board

Zylox-Tonbridge Medical Technology Co., Ltd.

Dr. Jonathon Zhong Zhao

Chairman and Executive Director

Hong Kong, November 29, 2021

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive Directors, and Dr. Jian Ji, Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive Directors.